DBV Technologies SA – (NASDAQ:DBVT) gapped up before the market opened on Monday . The stock had previously closed at $34.76, but opened at $34.90. DBV Technologies SA – shares last traded at $35.09, with a volume of 25,321 shares changing hands.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered DBV Technologies SA – from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. Jefferies Group reiterated a “buy” rating on shares of DBV Technologies SA – in a report on Wednesday, June 8th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $50.52.

The company’s market capitalization is $1.62 billion. The firm has a 50 day moving average of $32.19 and a 200-day moving average of $30.53.

Several hedge funds have bought and sold shares of DBVT. Jennison Associates LLC increased its stake in DBV Technologies SA – by 0.9% in the fourth quarter. Jennison Associates LLC now owns 721,775 shares of the company’s stock worth $26,208,000 after buying an additional 6,578 shares during the period. New York State Common Retirement Fund acquired a new stake in DBV Technologies SA – during the fourth quarter worth $2,551,000. Sei Investments Co. acquired a new stake in DBV Technologies SA – during the fourth quarter worth $1,577,000. Finally, Jennison Associates increased its stake in DBV Technologies SA – by 13.6% in the third quarter. Jennison Associates now owns 715,197 shares of the company’s stock worth $25,454,000 after buying an additional 85,573 shares during the period.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.